newsfilter
← Earnings
Earnings Releases·

Larimar Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $31.1 million ($0.29/share) for Q3 2026, a significant improvement from $47.7 million ($0.61/share) in Q3 2025, driven by a $19.3 million reduction in R&D manufacturing costs despite a rise in G&A expenses due to commercial acceleration.
  • Completed a rolling BLA submission for nomlabofusp targeting accelerated approval for Friedreich's ataxia, with the FDA indicating willingness to consider skin frataxin as a surrogate endpoint.
  • Provided future outlook targeting U.S. approval in mid-2027 and a potential launch in Q3 2027, contingent on FDA review and the progression of the FORWARD-FA Phase 3 study.
  • Maintained a cash runway extending into late Q2 2027 with $128.7 million in cash equivalents and marketable securities as of September 30, 2026.
  • Increased outstanding common shares to 104.6 million and preferred shares to 500,000 as of September 30, 2026, reflecting capital raised to support commercialization preparations.
Company
LARIMAR THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology